Abatacept for Crohn's Disease and Ulcerative Colitis
William J. Sandborn(University of San Diego), Stephen B. Hanauer(Northwestern University), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Yun Peng(Capital Medical University), Sheila Gujrathi(Bristol-Myers Squibb (Germany)), Stephan R. Targan(Cedars-Sinai Medical Center), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Brian Bressler(University of British Columbia), Allison Luo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Luisa Salter–Cid(Bristol-Myers Squibb (Germany)), Paul Rutgeerts(KU Leuven), Richard Aranda(Bristol-Myers Squibb (Germany)), Remo Panaccione(University of Calgary), K. Geboes(KU Leuven), Jean‐Frédéric Colombel(Mount Sinai Hospital)
Cited by 142
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k